Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70779 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Mohamed H Eldesouki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation.
Aim
We evaluated the incidence of MPNs among patients with IBD and clinical outcomes of IBD–MPN coexistence.
Methods
Two retrospective cohort analyses were conducted using the TriNetX database. First, adults with ulcerative colitis (UC) or Crohn's disease (CD) were compared with matched non‐IBD controls to estimate incident MPN risk. A coexistence second analysis included patients with UC or CD who developed MPNs and then were matched to IBD without MPN controls to assess 5‐year outcomes, including IBD‐related complications, surgical interventions, colorectal cancer (CRC) and primary sclerosing cholangitis (PSC). Medication subgroup analyses were performed to evaluate associations with MPN risk.
Results
After matching, 3873 patients with UC–MPN and 3474 patients with CD–MPN were included. Compared with matched non‐IBD controls, incident MPN risk was higher in UC (HR 1.60, p = 0.01) and CD (HR 1.56, p < 0.001). In CD, MPN coexistence was associated with higher risks of CRC (HR 1.52, p = 0.012), intestinal fistula (HR 2.84, p < 0.001), obstruction (HR 2.05, p < 0.001), perforation (HR 2.37, p < 0.001), small bowel resection (HR 3.69, p < 0.001) and colectomy (HR 2.10, p < 0.001). In UC, MPN coexistence was associated with higher risks of CRC (HR 1.50, p = 0.001), PSC (HR 1.75, p = 0.03) and pouchitis (HR 1.68, p = 0.003). Exposure to thiopurines (HR 1.28, p < 0.001) was associated with increased MPN risk, whereas TNF, IL‐23 and JAK inhibitors were not.
Conclusions
IBD is associated with increased MPN risk, and IBD–MPNs coexistence is associated with worse IBD‐related complications and malignancy risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
- Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Haematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Mohamed H Eldesouki, Ahmed Ibrahim
Zitieren
APA
Eldesouki, M. H., Ibrahim, A., Marey, M. M., Francis, F. F., Alsakarneh, S., Ayala, E., Shaukat, A., Farraye, F. A., & Hashash, J. G. (2026). Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70779
Vancouver
Eldesouki MH, Ibrahim A, Marey MM, Francis FF, Alsakarneh S, Ayala E, et al. Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70779
BibTeX
@article{Eldesouki2026,
author = {Eldesouki, Mohamed H and Ibrahim, Ahmed and Marey, Muhammed M and Francis, Fadi F and Alsakarneh, Saqr and Ayala, Ernesto and Shaukat, Aasma and Farraye, Francis A and Hashash, Jana G},
title = {Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70779}
}
EUVIMED